Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
In a worldwide deal excluding Asia, the two companies will split both revenues and development costs 50/50 in North America and Europe.
In a worldwide deal excluding Asia, the two companies will split both revenues and development costs 50/50 in North America and Europe.